The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial.

Scirica BM, Lincoff AM, Lingvay I, Bogdanski P, Buscemi S, Colhoun H, Craciun AE, Ezhov M, Hardt-Lindberg S, Kleist Jeppesen O, Matos ALSA, Node K and 7 more

Show all authors

Schiele F, Toplak H, van Beek A, Weeke PE, Wiviott SD, Deanfield J, Ryan D

Journal of the American College of Cardiology30 Aug 2024Cited by 40 (Europe PMC)

PMID39217559DOI10.1016/j.jacc.2024.08.007PepBankPUB-39217559

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and established cardiovascular disease without diabetes, semaglutide 2.4 mg lowered the rate of all-cause death versus placebo.
In plain wordsIn adults with overweight or obesity and heart disease, semaglutide lowered the rate of death from any cause more than placebo.
Peptide
Semaglutide
Outcome
DecreaseAll-cause death
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.81 ratio
all-cause death
Source sentences
Summary
Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95).
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755901
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and established cardiovascular disease, the rate of cardiovascular death was lower with semaglutide than with placebo, but the confidence interval included no difference.
In plain wordsIn adults with overweight or obesity and heart disease, heart-related deaths were not clearly lower with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
No significant changeCardiovascular death
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.85 ratio
cardiovascular death
Source sentences
Summary
Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95).
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755902
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and established cardiovascular disease, semaglutide lowered the rate of non-cardiovascular death versus placebo.
In plain wordsIn adults with overweight or obesity and heart disease, semaglutide lowered the rate of deaths from non-heart causes more than placebo.
Peptide
Semaglutide
Outcome
DecreaseNon-cardiovascular death
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.77 ratio
non-CV death
Source sentences
Summary
Participants assigned to semaglutide vs placebo had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95).
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755903
04HumanRandomized controlled trialEfficacy outcome
Sudden cardiac death was not significantly different between semaglutide and placebo.
In plain wordsSudden cardiac deaths were not clearly different between semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeSudden cardiac death
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Cardiovascular
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.89 ratio
sudden cardiac death
Source sentences
Summary
sudden cardiac death (98 vs 109; HR: 0.89; 95% CI: 0.68-1.17)
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755904
05HumanRandomized controlled trialEfficacy outcome
Undetermined death was not significantly different between semaglutide and placebo.
In plain wordsDeaths of undetermined cause were not clearly different between semaglutide and placebo.
Peptide
Semaglutide
Outcome
No significant changeUndetermined death
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.85 ratio
undetermined death
Source sentences
Summary
undetermined death (77 vs 90; HR: 0.85; 95% CI: 0.63-1.15)
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755905
06HumanRandomized controlled trialEfficacy outcome
Infection, the most common cause of non-cardiovascular death, caused fewer deaths with semaglutide than with placebo.
In plain wordsFewer people died from infection with semaglutide than with placebo.
Peptide
Semaglutide
Outcome
DecreaseDeath from infection
Study
n = 17,604
Comparator
Placebo
Outcome group
Mortality · Infection
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
hazard ratio
0.71 ratio
infection death
Source sentences
Summary
Infection was the most common cause of non-CV death and occurred at a lower rate in the semaglutide vs the placebo group (62 vs 87; HR: 0.71; 95% CI: 0.51-0.98).
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755906
07HumanRandomized controlled trialEfficacy outcome
Semaglutide did not reduce incident COVID-19 versus placebo.
In plain wordsSemaglutide did not lower the number of people who caught COVID-19 compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeIncident COVID-19
Study
n = 17,604
Comparator
Placebo
Outcome group
Infection and antimicrobial activity · Infection
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Source sentences
Summary
Semaglutide did not reduce incident COVID-19
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755907
08HumanRandomized controlled trialSafety outcome
Among participants who developed COVID-19, fewer treated with semaglutide had COVID-19-related serious adverse events than with placebo.
In plain wordsAmong people who got COVID-19, fewer on semaglutide had serious COVID-related problems than on placebo.
Peptide
Semaglutide
Outcome
DecreaseCOVID-19-related serious adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Infection
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
participants with COVID-19-related serious adverse events
232 participants
semaglutide
participants with COVID-19-related serious adverse events
277 participants
placebo
Source sentences
Summary
among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19-related serious adverse events (232 vs 277; P = 0.04
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755908
09HumanRandomized controlled trialEfficacy outcome
Among participants who developed COVID-19, fewer treated with semaglutide died of COVID-19 than with placebo.
In plain wordsAmong people who got COVID-19, fewer on semaglutide died of it than on placebo.
Peptide
Semaglutide
Outcome
DecreaseCOVID-19 death
Study
n: not reported in source
Comparator
Placebo
Outcome group
Mortality · Infection
Studied dose
2.4 mg once weekly · subcutaneous · mean 3.3 yearsAs given in this study (human).
Measurements
participants who died of COVID-19
43 participants
semaglutide
participants who died of COVID-19
65 participants
placebo
hazard ratio
0.66 ratio
COVID-19 death
Source sentences
Summary
among participants who developed COVID-19, fewer participants treated with semaglutide had COVID-19-related serious adverse events (232 vs 277; P = 0.04) or died of COVID-19 (43 vs 65; HR: 0.66; 95% CI: 0.44-0.96)
1 context sentence(design, population, supporting numbers)
Summary · context
The SELECT (Semaglutide Effects on Cardiovascular Outcomes in Patients With Overweight or Obesity) trial randomized 17,604 participants ≥45 years of age with a body mass index ≥27 kg/m² with established CV disease but without diabetes to once-weekly subcutaneous semaglutide 2.4 mg or plac…
Report a problemFND-3921755909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Novo Nordisk A/Sn = 17,60424 Oct 2018 to 29 Jun 2023

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 30 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.